Element Biosciences: Illumina ordered to pay damages, provide accounting of infringing activity

On July 8, 2026, a federal court in Delaware issued a ruling in the ongoing patent litigation between Element Biosciences and Illumina, Inc. The court ordered Illumina to pay damages and provide a detailed accounting of its alleged infringing activities related to genomic sequencing technologies. The ruling follows a series of procedural developments, including the denial of Illumina’s motion to dismiss Element’s claims and the adoption of a report and recommendation from the magistrate judge, which concluded that the motion lacked merit [62].

Element, a biotechnology firm focused on delivering high-quality, affordable sequencing solutions, has maintained that Illumina’s legal actions are anticompetitive and designed to limit market choice. The company emphasized its commitment to innovation and transparency, stating that the litigation would not disrupt its ability to supply products or support its customers.

The case, which was initially filed in September 2025, has seen extensive procedural activity, including the exchange of discovery materials, the filing of protective orders, and the submission of multiple motions. The court’s recent decision marks a significant development in the dispute, as it compels Illumina to account for its alleged infringement and sets the stage for further proceedings, including potential trial preparations.

Both parties have retained extensive legal representation, with numerous attorneys appearing pro hac vice in the case. The court has also issued scheduling orders to streamline the discovery process and ensure timely resolution of the matter.

As the case moves forward, investors and industry observers will be closely monitoring the financial and strategic implications for both companies. The outcome could influence the competitive landscape of the genomic sequencing market and set important legal precedents in patent litigation.